If you are not happy with the results below please do another search
ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
In a joint conference event yesterday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
The company’s U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb’s (BMY.N) blockbuster cancer drug Revlimid, which was launched in 2022.
“The APAC region reports the most asthma-related deaths. This underscores the urgent need for effective treatments and management strategies tailored to the unique challenges faced in the region. Addressing these challenges requires a multi-faceted approach, including enhanced patient education, early diagnosis, improved treatment accessibility, and adherence to therapies,” states GlobalData Analyst Sravani Meka.
The agency’s panel of independent advisers will on June 4 deliberate whether they should recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder, Lykos Therapeutics stated.
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker.
In the sea of content today, customers – HCPs and consumers alike – are overwhelmed with information. This content might be reaching them, but not effectively resonating and activating them to change behaviors. Cutting through this noise requires creative effectiveness that can only happen by harnessing the right data, technology and AI to drive next level audience understanding and as such, next level engagement.
Aldaia is president of H4B Chelsea. Her 20+ years in the industry includes leadership roles at Omnicom and WPP, with a dedicated focus on improving health outcomes through meaningful consumer and professional health communications.
Following the regulatory victory of Balversa in urothelial carcinoma, Johnson & Johnson on Friday continued its bladder cancer winning streak with an 82.8% complete response rate forTAR-200 in high-risk non-muscle invasive bladder cancer.
Andrew Baum, M.D. will play a vital role in advancing Pfizer’s long-term corporate strategic plan to maximize value for patients and shareholders. He will also be responsible for our portfolio analysis and prioritization functions, business development activities, strengthening our partnerships with the biotech ecosystem, and the commercial evaluation of our research pipeline.
